Home
About
Overview
Sharing Data
ORCID
Help
History (74)
Rationale for treatment and study design of tailor: a randomized phase III trial of second-line erlotinib versus docetaxel in the treatment of patients affected by advanced non-small-cell lung cancer with the absence of epidermal growth factor receptor mutations.
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system.
Caring for Patients With Cancer During the COVID-19 Outbreak in Italy.
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
See All 74 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012 Mar; 75(3):360-7.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Cisplatin
Female
Glutamates
Guanine
Humans
Male
Mesothelioma
Middle Aged
Multivariate Analysis
Pemetrexed
Platinum Compounds
Pleural Neoplasms
Retrospective Studies
Survival Rate
Treatment Outcome
authors with profiles
Marina Chiara Garassino